Insmed Incorporated, a global biopharmaceutical company, recently presented significant findings from their respiratory portfolio at the American Thoracic Society 2025 International Conference. Among the highlights were the results from the Phase 3 ASPEN trial of brensocatib, which demonstrated consistent efficacy and safety in treating non-cystic fibrosis bronchiectasis (NCFBE) across three key patient subgroups. These subgroups included adolescents aged 12 and older, patients receiving macrolide therapy, and individuals with varying blood eosinophil levels. The trial showed brensocatib's ability to reduce pulmonary exacerbations, delay the time to the first exacerbation, and slow lung function decline compared to a placebo, with a safety profile comparable to the overall trial population. Additionally, Insmed shared data from a post-hoc analysis on lung function and health economics, as well as insights from their expanded Phase 2 analysis of treprostinil palmitil inhalation powder in patients with pulmonary hypertension linked to interstitial lung disease. These findings underscore Insmed's commitment to advancing research and developing therapies for serious respiratory diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.